PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells

expression patterns and clinical implications

Claudio Luchini, Jerome Cros, Antonio Pea, Camilla Pilati, Nicola Veronese, Borislav Rusev, Paola Capelli, Andrea Mafficini, Alessia Nottegar, Lodewijk A.A. Brosens, Michaël Noë, G. Johan A. Offerhaus, Peter Chianchiano, Giulio Riva, Paola Piccoli, Claudia Parolini, Giuseppe Malleo, Rita T. Lawlor, Vincenzo Corbo, Nicola Sperandio & 5 others Mattia Barbareschi, Matteo Fassan, Liang Cheng, Laura D. Wood, Aldo Scarpa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), a variant of pancreatic ductal adenocarcinoma (PDAC), has a striking genetic similarity to PDAC but a significantly improved overall survival. We hypothesize that this difference could be due to the immune response to the tumor, and as such, we investigated the expression of PD-1, PD-L1, and CD163 in a series of UCOGC. To this aim, 27 pancreatic UCOGCs (11 pure and 16 PDAC-associated), 5 extrapancreatic tumors with osteoclast-like giant cells and 10 pancreatic anaplastic carcinomas were immunostained using antibodies against PD-1, PD-L1, and CD163. In pancreatic UCOGCs, PD-L1 was expressed in neoplastic cells of 17 (63%) of 27 cases, more often in cases with an associated PDAC (P =.04). Expression of PD-L1 was associated with poor prognosis, confirmed by multivariate analysis: patients with PD-L1–positive UCOGCs had a risk of all-cause mortality that was 3 times higher than did patients with PD-L1–negative UCOGCs (hazard ratio, 3.397; 95% confidence interval, 1.023-18.375; P =.034). PD-L1 expression on tumor cells was also associated with aberrant P53 expression (P =.035). PD-1 was expressed on rare lymphocytes in 12 UCOGCs (44.4%), mainly located at the tumor periphery. CD163 was expressed on histiocytes, with a diffuse and strong staining pattern in all UCOGCs. Extrapancreatic tumors with osteoclast-like giant cells showed very similar staining patterns for the same proteins. Anaplastic carcinomas have some similarities to UCOGCs, but PD-L1 has no prognostic roles. Our results may have important implications for immunotherapeutic strategies in UCOGCs; these tumors may also represent a model for future therapeutic approaches against PDAC.

Original languageEnglish (US)
Pages (from-to)157-165
Number of pages9
JournalHuman Pathology
Volume81
DOIs
StatePublished - Nov 1 2018

Fingerprint

Osteoclasts
Giant Cells
Adenocarcinoma
Carcinoma
Neoplasms
Staining and Labeling
Histiocytes
Pancreatic Carcinoma
Multivariate Analysis
Lymphocytes
Confidence Intervals
Survival
Mortality
Antibodies
Proteins

Keywords

  • Osteoclast
  • Pancreatic cancer
  • PDAC
  • Tumor-associated macrophages
  • UCOGC

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells : expression patterns and clinical implications. / Luchini, Claudio; Cros, Jerome; Pea, Antonio; Pilati, Camilla; Veronese, Nicola; Rusev, Borislav; Capelli, Paola; Mafficini, Andrea; Nottegar, Alessia; Brosens, Lodewijk A.A.; Noë, Michaël; Offerhaus, G. Johan A.; Chianchiano, Peter; Riva, Giulio; Piccoli, Paola; Parolini, Claudia; Malleo, Giuseppe; Lawlor, Rita T.; Corbo, Vincenzo; Sperandio, Nicola; Barbareschi, Mattia; Fassan, Matteo; Cheng, Liang; Wood, Laura D.; Scarpa, Aldo.

In: Human Pathology, Vol. 81, 01.11.2018, p. 157-165.

Research output: Contribution to journalArticle

Luchini, C, Cros, J, Pea, A, Pilati, C, Veronese, N, Rusev, B, Capelli, P, Mafficini, A, Nottegar, A, Brosens, LAA, Noë, M, Offerhaus, GJA, Chianchiano, P, Riva, G, Piccoli, P, Parolini, C, Malleo, G, Lawlor, RT, Corbo, V, Sperandio, N, Barbareschi, M, Fassan, M, Cheng, L, Wood, LD & Scarpa, A 2018, 'PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications', Human Pathology, vol. 81, pp. 157-165. https://doi.org/10.1016/j.humpath.2018.07.006
Luchini, Claudio ; Cros, Jerome ; Pea, Antonio ; Pilati, Camilla ; Veronese, Nicola ; Rusev, Borislav ; Capelli, Paola ; Mafficini, Andrea ; Nottegar, Alessia ; Brosens, Lodewijk A.A. ; Noë, Michaël ; Offerhaus, G. Johan A. ; Chianchiano, Peter ; Riva, Giulio ; Piccoli, Paola ; Parolini, Claudia ; Malleo, Giuseppe ; Lawlor, Rita T. ; Corbo, Vincenzo ; Sperandio, Nicola ; Barbareschi, Mattia ; Fassan, Matteo ; Cheng, Liang ; Wood, Laura D. ; Scarpa, Aldo. / PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells : expression patterns and clinical implications. In: Human Pathology. 2018 ; Vol. 81. pp. 157-165.
@article{16fef4f019a8442aabb295115c03d8fa,
title = "PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications",
abstract = "Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), a variant of pancreatic ductal adenocarcinoma (PDAC), has a striking genetic similarity to PDAC but a significantly improved overall survival. We hypothesize that this difference could be due to the immune response to the tumor, and as such, we investigated the expression of PD-1, PD-L1, and CD163 in a series of UCOGC. To this aim, 27 pancreatic UCOGCs (11 pure and 16 PDAC-associated), 5 extrapancreatic tumors with osteoclast-like giant cells and 10 pancreatic anaplastic carcinomas were immunostained using antibodies against PD-1, PD-L1, and CD163. In pancreatic UCOGCs, PD-L1 was expressed in neoplastic cells of 17 (63{\%}) of 27 cases, more often in cases with an associated PDAC (P =.04). Expression of PD-L1 was associated with poor prognosis, confirmed by multivariate analysis: patients with PD-L1–positive UCOGCs had a risk of all-cause mortality that was 3 times higher than did patients with PD-L1–negative UCOGCs (hazard ratio, 3.397; 95{\%} confidence interval, 1.023-18.375; P =.034). PD-L1 expression on tumor cells was also associated with aberrant P53 expression (P =.035). PD-1 was expressed on rare lymphocytes in 12 UCOGCs (44.4{\%}), mainly located at the tumor periphery. CD163 was expressed on histiocytes, with a diffuse and strong staining pattern in all UCOGCs. Extrapancreatic tumors with osteoclast-like giant cells showed very similar staining patterns for the same proteins. Anaplastic carcinomas have some similarities to UCOGCs, but PD-L1 has no prognostic roles. Our results may have important implications for immunotherapeutic strategies in UCOGCs; these tumors may also represent a model for future therapeutic approaches against PDAC.",
keywords = "Osteoclast, Pancreatic cancer, PDAC, Tumor-associated macrophages, UCOGC",
author = "Claudio Luchini and Jerome Cros and Antonio Pea and Camilla Pilati and Nicola Veronese and Borislav Rusev and Paola Capelli and Andrea Mafficini and Alessia Nottegar and Brosens, {Lodewijk A.A.} and Micha{\"e}l No{\"e} and Offerhaus, {G. Johan A.} and Peter Chianchiano and Giulio Riva and Paola Piccoli and Claudia Parolini and Giuseppe Malleo and Lawlor, {Rita T.} and Vincenzo Corbo and Nicola Sperandio and Mattia Barbareschi and Matteo Fassan and Liang Cheng and Wood, {Laura D.} and Aldo Scarpa",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.humpath.2018.07.006",
language = "English (US)",
volume = "81",
pages = "157--165",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells

T2 - expression patterns and clinical implications

AU - Luchini, Claudio

AU - Cros, Jerome

AU - Pea, Antonio

AU - Pilati, Camilla

AU - Veronese, Nicola

AU - Rusev, Borislav

AU - Capelli, Paola

AU - Mafficini, Andrea

AU - Nottegar, Alessia

AU - Brosens, Lodewijk A.A.

AU - Noë, Michaël

AU - Offerhaus, G. Johan A.

AU - Chianchiano, Peter

AU - Riva, Giulio

AU - Piccoli, Paola

AU - Parolini, Claudia

AU - Malleo, Giuseppe

AU - Lawlor, Rita T.

AU - Corbo, Vincenzo

AU - Sperandio, Nicola

AU - Barbareschi, Mattia

AU - Fassan, Matteo

AU - Cheng, Liang

AU - Wood, Laura D.

AU - Scarpa, Aldo

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), a variant of pancreatic ductal adenocarcinoma (PDAC), has a striking genetic similarity to PDAC but a significantly improved overall survival. We hypothesize that this difference could be due to the immune response to the tumor, and as such, we investigated the expression of PD-1, PD-L1, and CD163 in a series of UCOGC. To this aim, 27 pancreatic UCOGCs (11 pure and 16 PDAC-associated), 5 extrapancreatic tumors with osteoclast-like giant cells and 10 pancreatic anaplastic carcinomas were immunostained using antibodies against PD-1, PD-L1, and CD163. In pancreatic UCOGCs, PD-L1 was expressed in neoplastic cells of 17 (63%) of 27 cases, more often in cases with an associated PDAC (P =.04). Expression of PD-L1 was associated with poor prognosis, confirmed by multivariate analysis: patients with PD-L1–positive UCOGCs had a risk of all-cause mortality that was 3 times higher than did patients with PD-L1–negative UCOGCs (hazard ratio, 3.397; 95% confidence interval, 1.023-18.375; P =.034). PD-L1 expression on tumor cells was also associated with aberrant P53 expression (P =.035). PD-1 was expressed on rare lymphocytes in 12 UCOGCs (44.4%), mainly located at the tumor periphery. CD163 was expressed on histiocytes, with a diffuse and strong staining pattern in all UCOGCs. Extrapancreatic tumors with osteoclast-like giant cells showed very similar staining patterns for the same proteins. Anaplastic carcinomas have some similarities to UCOGCs, but PD-L1 has no prognostic roles. Our results may have important implications for immunotherapeutic strategies in UCOGCs; these tumors may also represent a model for future therapeutic approaches against PDAC.

AB - Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), a variant of pancreatic ductal adenocarcinoma (PDAC), has a striking genetic similarity to PDAC but a significantly improved overall survival. We hypothesize that this difference could be due to the immune response to the tumor, and as such, we investigated the expression of PD-1, PD-L1, and CD163 in a series of UCOGC. To this aim, 27 pancreatic UCOGCs (11 pure and 16 PDAC-associated), 5 extrapancreatic tumors with osteoclast-like giant cells and 10 pancreatic anaplastic carcinomas were immunostained using antibodies against PD-1, PD-L1, and CD163. In pancreatic UCOGCs, PD-L1 was expressed in neoplastic cells of 17 (63%) of 27 cases, more often in cases with an associated PDAC (P =.04). Expression of PD-L1 was associated with poor prognosis, confirmed by multivariate analysis: patients with PD-L1–positive UCOGCs had a risk of all-cause mortality that was 3 times higher than did patients with PD-L1–negative UCOGCs (hazard ratio, 3.397; 95% confidence interval, 1.023-18.375; P =.034). PD-L1 expression on tumor cells was also associated with aberrant P53 expression (P =.035). PD-1 was expressed on rare lymphocytes in 12 UCOGCs (44.4%), mainly located at the tumor periphery. CD163 was expressed on histiocytes, with a diffuse and strong staining pattern in all UCOGCs. Extrapancreatic tumors with osteoclast-like giant cells showed very similar staining patterns for the same proteins. Anaplastic carcinomas have some similarities to UCOGCs, but PD-L1 has no prognostic roles. Our results may have important implications for immunotherapeutic strategies in UCOGCs; these tumors may also represent a model for future therapeutic approaches against PDAC.

KW - Osteoclast

KW - Pancreatic cancer

KW - PDAC

KW - Tumor-associated macrophages

KW - UCOGC

UR - http://www.scopus.com/inward/record.url?scp=85053819159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053819159&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2018.07.006

DO - 10.1016/j.humpath.2018.07.006

M3 - Article

VL - 81

SP - 157

EP - 165

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -